Newsletter | March 10, 2021

03.10.21 -- Listen Now - The FDA's Progressive Appeal, AI And The Human Genome, And More

Listen Now: Our Latest Podcast Episodes

On February 22, our podcast host suffered a distributed denial of service (DDoS) attack that may have prevented you from hearing our talk on AI in genomics with NeuBase CEO, Dr. Dietrich Stephan. The issue has been resolved, and it's an episode you don't want to miss! While you're at it, check out these new episodes of Business of Biotech and Life Science Connect. Don’t forget to subscribe so you never miss an episode!


AI And The Human Genome With NeuBase CEO, Dr. Dietrich Stephan

NeuBase Therapeutics CEO, Dr. Dietrich Stephan, is recognized as a pioneer in the field of genomic precision medicine. On this episode of Business of Biotech, Dr. Stephan shares how artificial intelligence is shaping the acceleration of genomic medicine discovery at NeuBase and beyond, with plenty of practical insight on how to adopt and leverage the technology.

The FDA's Progressive Appeal, Featuring Allan Shaw

Allan Shaw rejoins the Business of Biotech podcast with candid commentary on the unprecedented pace of biopharma innovation, and how the FDA is doing in its equally unprecedented effort to keep pace. In particular, Shaw shares his take on the advance of cell and gene therapies and his observations on the outsized approval rate for orphan disease and oncology therapies. 

Allogeneic Cell Therapy Manufacturing Featuring Celyad CEO, Filippo Petti

Join Matt Pillar and Erin Harris as they catch up with Celyad Oncology chief, Filippo Petti, on his company's differentiated approach to the discovery and development of allogeneic CAR T-cell therapy candidates for the treatment of cancer. Petti shares the technology and how the company intends to scale in-house manufacturing in its Belgium-based manufacturing facility.


Are Decentralized Trials Finally Here To Stay?

Will decentralized clinical trials continue to be a hot topic even after the pandemic or will pharma companies revert to their old ways? Our guest, editor, Ed Miseta, weighs in on this timely topic.